secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2026-01-14T23:59:59+00:00
Accession:  0000875045-26-000003
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Biogen expects ~$222M pre-tax charge in Q4 2025 for IPR&D and milestone costs; EPS impact ~$1.26
--------------------------------------------------------------------------------

- Q4 2025 acquired IPR&D, upfront and milestone expense estimated at ~$222M pre-tax.
- Estimated impact of $1.26 per diluted share on both GAAP and non-GAAP EPS.
- Expense line item newly presented separately since Q1 2025.
- Final Q4 2025 results not finalized; subject to closing procedures.
- Company does not forecast such expenses due to uncertainty in timing and magnitude.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504526000003/0000875045-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504526000003/biib-20260113.htm
  HTML page:      https://secwatch.observer/filing/0000875045-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer